Credelio Chewable Tablets for dogs (1.3 - 2.5kg) 56mg

Item Number: CREDELD3

  • pack of 6

    Usually dispatched on Tuesday if ordered within 1 hours and 21 minutes

    £ 28.45

Total: £0.00

Description

Target species
Dogs.

Indications for use, specifying the target species
For the treatment of flea and tick infestations in dogs.

This veterinary medicinal product provides immediate and persistent killing activity for 1 month for fleas (Ctenocephalides felis and C. canis) and ticks (Rhipicephalus sanguineus, Ixodes ricinus,
I. hexagonus and Dermacentor reticulatus).
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

Contraindications
Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Special warnings for each target species
Parasites need to start feeding on the host to become exposed to lotilaner; therefore the risk of the transmission of parasite borne diseases cannot be completely excluded.

Special precautions for use
Special precautions for use in animals
All safety and efficacy data have been acquired from dogs and puppies 8 weeks of age and older and 1.3 kg of body weight and greater. Use of this veterinary medicinal product in puppies younger than 8 weeks of age or less than 1.3 kg of body weight should be based on a benefit-risk assessment by the responsible veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals
Wash hands after handling the product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.

Adverse reactions (frequency and seriousness)
None known.

Use during pregnancy, lactation or lay
Laboratory studies in rats have not produced any evidence of teratogenic effects, or any adverse effect on the reproductive capacity of males and females. The safety of the veterinary medicinal product in breeding, pregnant and lactating dogs has not been established. Use only according to the benefit-risk assessment of the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction
None known. During clinical testing, no interactions between Credelio chewable tablets and routinely used veterinary medicinal products were observed.

Amounts to be administered and administration route
For oral use.
The veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 20 to 43 mg lotilaner/kg bodyweight.

Strength and number of tablets to be administered
Bodyweight of dog (kg)
Credelio 56 mg
Credelio 112 mg
Credelio 225 mg
Credelio 450 mg
Credelio 900 mg
1.3-2.5
1
>2.5-5.5
1
>5.5-11.0
1
>11.0-22.0
1
>22.0-45.0
1
>45
Appropriate combination of tablets

Appropriate combination of tablets
The veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 20 to 43 mg lotilaner/kg bodyweight.
Use an appropriate combination of available strengths to achieve the recommended dose of 20– 43 mg/kg.
Credelio is a palatable chewable flavoured tablet. Administer the chewable tablet(s) monthly with or after food.

Overdose (symptoms, emergency procedures, antidotes), if necessary
No adverse reactions were observed following oral administration to puppies aged 8–9 weeks and weighing 1.3–3.6 kg treated with overdoses of up to 5 times the maximum recommended dose (43 mg, 129 mg and 215 mg lotilaner/kg bodyweight) on eight occasions at monthly intervals.

Withdrawal period(s)
Not applicable.

Pharmacological particulars
Pharmacotherapeutic group: ectoparasiticides for systemic use, isoxazolines.
ATCvet code: QP53BE04

Pharmacodynamic properties
Lotilaner, a pure enantiomer from the isoxazoline class is active against fleas (Ctenocephalides felis and Ctenocephalides canis) as well as the tick species Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus.
Lotilaner is a potent inhibitor of gamma–aminobutyric acid (GABA)-gated chloride channels, resulting in rapid death of ticks and fleas. The activity of lotilaner was not affected by resistance to organochlorines (cyclodienes, e.g. dieldrin), phenylpyrazoles (e.g. fipronil), neonicotinoids (e.g. imidacloprid), formamidines (e.g. amitraz) and pyrethroids (e.g. cypermethrin).
For fleas, the onset of efficacy is within 4 hours of attachment for one month after product administration. Fleas on the animal prior to administration are killed within 6 hours.
For ticks, the onset of efficacy is within 48 hours of attachment for one month after product administration. Existing I. ricinus ticks on the animal prior to administration are killed within 8 hours.
The veterinary medicinal product kills existing and newly emerged fleas on dogs before they can lay eggs. Therefore, the product breaks the flea life cycle and prevents environmental flea contamination in areas to which the dog has access.

Pharmacokinetic particulars
Following oral administration, lotilaner is readily absorbed and peak blood concentration is reached within 2 hours. Food enhances the absorption. The terminal half-life is approximately 4 weeks. This long terminal half-life provides effective blood concentrations for the entire duration of the inter- dosing interval.
The major route of elimination is biliary excretion and renal excretion is the minor route of elimination (less than 10% of the dose). Lotilaner is metabolized to a small extent into more hydrophilic compounds which are observed in faeces and urine.

Pharmaceutical particulars
List of excipients
Cellulose, powdered
Lactose monohydrate
Silicified microcrystalline cellulose
Meat dry flavour
Crospovidone
Povidone K30
Sodium laurilsulfate
Silica, colloidal anhydrous
Magnesium stearate

Incompatibilities
Not applicable.

Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Special precautions for storage
This medicinal product does not require any special storage conditions.

Nature and composition of immediate packaging
The tablets are packaged in aluminium/aluminium blisters packaged into an outer cardboard box. Each tablet strength is available in pack sizes of 1, 3 or 6 tablets.
Not all pack sizes may be marketed.

Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Reviews